Abstract
We thank the editors for allowing us to reply to the exhaustive commentary by Professor Sohan Singh Hayerh to our recent review. 1 Limaye K. Wall M. Uwaydat S. et al. Is management of centralretinal artery occlusion the next frontier in cerebrovascular diseases?. J Stroke Cerebrovasc Dis. 2018; 27 ([Epub ahead of print]): 30321-30325https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.06.006 Abstract Full Text Full Text PDF Scopus (13) Google Scholar We note that his criticisms of our paper are quite similar to those that he submitted in response to the EAGLE trial. 2 Hayreh S.S. Comment re: multicenter study of the European Assessment Group for Lysis in the Eye (EAGLE) for the treatment of central retinal artery occlusion: design issues and implications. Graefes Arch Clin Exp Ophthalmol. 2007; 245 (author reply 467-70): 464-466https://doi.org/10.1007/s00417-006-0473-5 Crossref PubMed Scopus (18) Google Scholar The response by Feltgen et al 3 Feltgen N. Schmidt D. Schumacher M. Response to comment: multicenter study of the European Assessment Group for Lysis in the Eye (EAGLE-Group) for the treatment of central retinal artery occlusion: design issues and implications. Graefes Arch Clin Exp Ophthalmol. 2007; 245 (EAGLE study report no. 1): 467-470 Crossref Scopus (8) Google Scholar has answered the limitations of the points he raises and hence we do not wish to again reiterate the same here. Is Management of Central Retinal Artery Occlusion the Next Frontier in Cerebrovascular Diseases?Journal of Stroke and Cerebrovascular DiseasesVol. 27Issue 10PreviewCentral retinal artery occlusion (CRAO) is a medical emergency that, if not treated, may result in irreversible loss of vision. It continues to be an important cause for acute painless loss of vision. Amaurosis fugax or “transient CRAO” has long been considered an equivalent of transient cerebral ischemic event. Animal models, in addition to data from retrospective and randomized clinical studies, provide valuable insights into the time interval for irreversible retinal ischemia. Subset analyses from 2 large studies of patients with CRAO show benefit from treatment with thrombolysis within 6 hours from symptoms onset. Full-Text PDF
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
